Baxter International Inc. has joined forces with Miromatrix Medical Inc. to advance the development of bioengineered organs for patients with acute liver failure (ALF). Under the collaborative research agreement, Baxter will combine its Prismax system with Miromatrix's single-use bioengineered liver, miroliver, to provide external support to patients' native livers as they await transplant or potential regeneration.